Long-Term Immune Persistence of attenuated varicella vaccine Injected two dose among aged 13 to 17 years population

Trial Profile

Long-Term Immune Persistence of attenuated varicella vaccine Injected two dose among aged 13 to 17 years population

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 May 2016

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Sponsors Changchun Changsheng Life Sciences
  • Most Recent Events

    • 02 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top